MSB 1.10% 91.5¢ mesoblast limited

Bitter Pill, page-5

  1. 27 Posts.
    lightbulb Created with Sketch. 21
    A product might work and yet not get registered due to stuff-ups in the trial design and thereafter, not achieving their endpoints. Regulators will only approve based on the endpoints.

    That's the nature and risk of investing in biotechs and pharma companies.

    The one saving grace is that the all cause ARDS Ph III trials that NVS will fund (and hopefully provide expertise in properly designing the study) be successful due to NVS input.

    My position in MSB is small so am happy to leave it aside and wait patiently for the recovery.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
91.5¢
Change
0.010(1.10%)
Mkt cap ! $1.044B
Open High Low Value Volume
93.0¢ 93.5¢ 90.5¢ $4.638M 5.036M

Buyers (Bids)

No. Vol. Price($)
9 152669 91.0¢
 

Sellers (Offers)

Price($) Vol. No.
92.5¢ 51069 3
View Market Depth
Last trade - 16.10pm 07/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.